The functions of plasminogen activator inhibitor-1: Do we have all the pieces of PAI?

Thrombosis Research

Volumn 117, Issue 5, 2006, Pages 483-486

  Mulligan Kehoe, Mary Jo ^a   Schwartz, Gary N ^a,b   Zacharski, Leo R ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE RECEPTOR; VITRONECTIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISSOCIATION; EDITORIAL; FIBRINOLYSIS; GENE EXPRESSION REGULATION; GENE SEQUENCE; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

BINDING SITES; GENE EXPRESSION REGULATION; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; VITRONECTIN;

EID: 33644662485     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.05.019     Document Type: Editorial

References (48)

1. H.R. Linjen Pleiotrophic functions of plasminogen activator inhibitor-1 J Thromb Haemost 3 2004 35 45
2. J. Keijer, M. Linders, A.J. van Zonneveld, H.J. Ehrlich, J.P. de Boer, and H. Pannekoek The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance Blood 78 1991 401 409
3. H.J. Ehrlich, R.K. Gebbink, K.T. Preissner, J. Keijer, N.L. Esmon, and K. Mertens Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix J Cell Biol 115 1991 1773 1781
4. H.J. Ehrlich, R.K. Gebbink, J. Keijer, and H. Pannekoek Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin J Biol Chem 267 1992 11606 11611
5. G. Deng, S.A. Curriden, G. Hu, R.P. Czekay, and D.J. Loskutoff Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin J Cell Physiol 189 2001 23 33
6. D.A. Waltz, L.R. Natkin, R.M. Fujita, Y. Wei, and H.A. Chapman Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin J Clin Invest Chem 100 1997 58 67
7. M.J. Mulligan-Kehoe, R. Wagner, C. Wieland, and R. Powell A truncated plasminogen activator inhibitor-1 protein induces and inhibits angiostatin (kringles 1-3), a plasminogen cleavage product J Biol Chem 276 2001 8588 8596
8. M.J. Mulligan-Kehoe, H.K. Kleinman, M. Drinane, R.J. Wagner, C. Wieland, and R.J. Powell A truncated plasminogen activator inhibitor-1 protein blocks the availability of heparin-binding vascular endothelial growth factor A isoforms J Biol Chem 277 2002 49077 49089
9. B. De Taeye, G. Compernolle, M. Dewilde, W. Biesemans, and P.J. Declerck Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1 J Biol Chem 278 2003 23899 23905
10. T. Wind, J.K. Jensen, D.M. Dupont, P. Kulig, and P.A. Andreasen Mutational analysis of plasminogen activator inhibitor-1 Eur J Biochem 270 2003 1680 1688
11. D.A. Lawrence, S. Palaniappan, S. Stefansson, S.T. Olson, A.M. Francis-Chmura, and J.D. Shore Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin J Biol Chem 272 1997 7676 7680
12. G.A. McMahon, E. Petitclerc, S. Stefansson, E. Smith, M.K. Wong, and R.J. Westrick Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis J Biol Chem 276 2001 33964 33968
13. K. Bajou, V. Masson, R.D. Gerard, P.M. Schmitt, V. Albert, and M. Praus The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies J Cell Biol 152 2001 777 784
14. S. Stefansson, E. Petitclerc, M.K. Wong, G.A. McMahon, P.C. Brooks, and D.A. Lawrence Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1 J Biol Chem 276 2001 8135 8141
15. E. Bacharach, A. Itin, and E. Keshet In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis Proc Natl Acad Sci U S A 89 1992 10686 10690
16. H.W. Schnaper, E.S. Barnathan, A. Mazar, S. Maheshwari, S. Ellis, and S.L. Cortez Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways J Cell Physiol 165 1995 107 118
17. R. Hildenbrand, I. Dilger, A. Horlin, and H.J. Stutte Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer Pathol Res Pract 191 1995 403 409
18. C. Isogai, W.E. Laug, H. Shimada, P.J. Declerck, M.F. Stins, and D.L. Durden Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin Cancer Res 61 2001 5587 5594
19. F. Janicke, M. Schmitt, and H. Graeff Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer Semin Thromb Hemost 17 1991 303 312
20. L. Christensen, A.C. Wiborg Simonsen, C.W. Heegaard, S.K. Moestrup, J.A. Andersen, and P.A. Andreasen Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas Int J Cancer 66 1996 441 452
21. V. Costantini, A. Sidoni, R. Deveglia, O.A. Cazzato, G. Bellezza, and I. Ferri Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues Cancer 77 1996 1079 1088
22. B.S. Nielsen, M. Sehested, L. Kjeldsen, N. Borregaard, J. Rygaard, and K. Dano Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer Lab Invest 74 1996 168 177
23. N. Harbeck, U. Alt, U. Berger, A. Kruger, C. Thomssen, and F. Janicke Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy Clin Cancer Res 7 2001 2757 2764
24. M.P. Look, W.L. van Putten, M.J. Duffy, N. Harbeck, I.J. Christensen, and C. Thomssen Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients J Natl Cancer Inst 94 2002 116 128
25. P.A. Andreasen, L. Kjoller, L. Christensen, and M.J. Duffy The urokinase-type plasminogen activator system in cancer metastasis: a review Int J Cancer 72 1997 1 22
26. M. Schmitt, N. Harbeck, C. Thomssen, O. Wilhelm, V. Magdolen, and U. Reuning Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy Thromb Haemost 78 1997 285 296
27. M.J. Duffy, P. O'Grady, D. Devaney, L. O'Siorain, J.J. Fennelly, and H.J. Lijnen Urokinase-plasminogen activator, a marker for aggressive breast cancers Cancer 62 1988 531 533
28. F. Janicke, M. Schmitt, L. Pache, K. Ulm, N. Harbeck, and H. Hofler Urokinase (uPA) and its inhibitor PAI-1 are strong, independent prognostic factors in node negative breast cancer Breast Cancer Res Treat 24 1993 195 208
29. N. Harbeck, P. Dettmar, C. Thomssen, U. Berger, K. Ulm, and R. Kates Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers. Six year median follow-up Br J Cancer 80 1999 419 426
30. N. Harbeck, C. Meisner, A. Prechtl, M. Untch, H.-K. Selbmann, and F. Sweep Level-I evidence for prognostic and predictive impact of uPA and PAI-1 in node-negative breast cancer provided by second scheduled analysis of multicenter Chemo-N0 therapy trial Breast Cancer Res Treat 69 2001 19a
31. P. Manders, V.C. Tjan-Heijnen, P.N. Span, N. Grebenchtchikov, A. Geurts-Moespot, and D.T. van Tienoven Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma Cancer 101 2004 486 494
32. T. Cufer, I. Vrhovec, and S. Borstnar Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival Int J Biol Markers 17 2002 33 41
33. N. Harbeck, R. Kates, and M. Schmitt Clinical relevance of invasion factors uPA and PAI-1 for individualized therapy decisions in primary breast cancer is greatest when used in combination J Clin Oncol 20 2002 1000 1009
34. M.E. Meijer-van Gelder, M.P. Look, H.A. Peters, M. Schmitt, N. Brunner, and N. Harbeck Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease Cancer Res 64 2004 4563 4568
35. P. Manders, V.C. Tjan-Heijnen, P.N. Span, N. Grebenchtchikov, A.J. Geurts-Moespot, and D.T. van Tienoven The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer Thromb Haemost 91 2004 514 521
36. N. Harbeck, R.E. Kates, M.P. Look, M.E. Meijer-Van Gelder, J.G. Klijn, and A. Kruger Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424) Cancer Res 62 2002 4617 4622
37. F. Janicke, A. Prechtl, C. Thomssen, N. Harbeck, C. Meisner, and M. Untch Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 J Natl Cancer Inst 93 2001 913 920
38. P. Manders, V.C. Tjan-Heijnen, P.N. Span, N. Grebenchtchikov, J.A. Foekens, and L.V. Beex Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer Cancer Res 64 2004 659 664
39. H.R. Lijnen Plasmin and matrix metalloproteinases in vascular remodeling Thromb Haemost 86 2001 324 333
40. K. Houck, D. Leung, A. Rowland, J. Winer, and N. Ferrara Dual regulation of vesicular endothelial growth factor bioavailability by genetic and proteolytic mechanisms J Biol Chem 267 1992 26031 26037
41. T. Kietzman, U. Roth, and K. Jungerman Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia inducible factor-1 in rat hepatocytes Blood 94 1999 4177 4185
42. G.L. Wang, and G.L. Semenza Purification and characterization of hypoxia inducible factor 1 J Biol Chem 270 1995 1230 1237
43. S. Dennler, S. Itoh, D. Vivien, P. ten Dijke, S. Huet, and J.M. Gauthier Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-1 gene EMBO J 17 1998 3091 3100
44. M.S. Sawdey, and D.J. Loskutoff Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta J Clin Invest 88 1991 1346 1353
45. P. Eriksson, B. Kallin, F.M. van't Hooft, P. Bavenholm, and A. Hamsten Allele-specific increase in basal transcription of the plasminogen activator inhibitor-1 gene is associated with myocardial infarction Proc Natl Acad Sci 92 1995 1851 1855
46. M. Stegnar, P. Uhrin, P. Peternel, A. Mavri, B. Salobir-Pajnic, and J. Stare The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism Thromb Haemost 79 1998 975 979
47. A. Gardemann, J. Lohre, N. Katz, H. Tillmanns, F.W. Hehrlein, and W. Haberbosch The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease Thromb Haemost 82 1999 1121 1126
48. R. Castello, F. España, C. Vázquez, C. Fuster, S.M. Almenar, and J. Aznar Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity Thromb. Res. 117 2006 487 492 10.1016/j.thromres.2005.03.025 (this issue)